COMMON STOCK TRANSACTIONS |
9 Months Ended |
|---|---|
Jan. 31, 2024 | |
| Equity [Abstract] | |
| COMMON STOCK TRANSACTIONS |
NOTE 5 – COMMON STOCK TRANSACTIONS
A summary of the Company’s compensatory stock activity and related weighted average grant date fair value information for the three and nine months ended January 31, 2024 and 2023 is as follows:
In January 2022, the Company awarded shares of common stock to the executive officers of the Company as part of their compensation agreements for 2022. During the nine months ended January 31, 2024 and 2023, the Company recorded a non-cash compensation expense in the amount of $ and $, respectively. There were unvested shares as of January 31, 2024 and 2023, respectively. Two of the executive officers terminated their services in October 2022 and pursuant to their separation agreements the shares were fully vested.
During the nine months ended January 31, 2023, three non-employee members of the Board were issued shares of common stock pursuant to their Director Letter Agreements (“DLAs”) in respect of their service during that year. The shares were fully vested upon issuance. The Company recorded a non-cash expense of $ for the three months ended January 31, 2024 and 2023, respectively, and $ and $ for the nine months ended January 31, 2024 and 2023, respectively. There were unvested shares remaining related to such DLAs as of January 31, 2024 and 2023, respectively.
All shares were issued without registration under the Securities Act of 1933 as amended (“Securities Act”) in reliance upon the exemption afforded by Section 4(a)(2) of the Securities Act.
There were shares granted, vested or expired during the nine months ended January 31, 2024.
|